| Nov 9th (Friday) | ||||
|---|---|---|---|---|
| 구 분 | A Room | B Room | C Room | D Room |
| 09:00 - | 등록 | |||
| 09:30 - 12:20 | Working Party I: MPN | Working Party II: Histiocytosis | Working Party III: RBC Disorder | |
| Session I 좌장: 박진희 |
Session I: Highlights of Histiocyte Society Annual Meeting 2018 좌장: 정낙균 |
좌장: 정혜림/한진영 |
||
| [9:30-10:00] Genetic-pathologic characterization of myeloproliferative neoplasms: Application of next- generation sequencing 김명신 (가톨릭의대) |
[09:30-10:00] LCH topics 유철주 (연세의대) |
Laboratory tests for the assessment of iron metabolism 김미영 (한림의대) |
||
| [10:00-10:20] Diagnosis and approach to pre-fibrotic MF 박상혁 (울산의대) |
[10:00-10:30] HLH topics
서종진 (울산의대) |
|||
| [10:30-10:50] Coffee break | ||||
| [10:20-10:40] Clinical map of pre-fibrotic MF patients 문영철 (이화의대) |
Session II: HLH & other Immune Dysregulation Disorders 좌장: 임호준 |
Iron-refractory iron deficiency anemia and TMPRSS6 mutation
최형수 (서울의대) |
||
| Session II 좌장: 엄기성 |
[10:50-11:30] EBV related HLH and chronic active EBV disease in Japan Akihisa Sawada (Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan) |
|||
| [10:50-11:20] Pivotal studies guiding the treatment and challenges in PV/ET 김민경 (영남의대) |
||||
| [11:20-11:50] Pivotal studies guiding the treatment and challenges in MF 배성화 (대구가톨릭의대) |
[11:30-12:00] Immune dysregulation disorders & HLH 홍경택(서울의대) |
Iron-resistant iron deficiecy anemia 임상적 진단 및 치료경험
엄지은 (한양의대) |
||
| [11:50-12:20] Nonmyeloablative transplantation in MF 김성용 (건국의전원) |
[12:00-12:30] Lymphoma associated HLH
홍준식(서울의대) |
|||
| 12:20 - 12:40 | Break | |||
| 12:40 - 13:20 | Special Lecture
좌장: 윤휘중 (대한혈액학회 회장) |
|||
| Genomics in myeloid malignancy
김형준 (대한혈액학회 이사장) |
||||
| 13:20 - 13:40 | Break | |||
| 13:40 - 16:40 | Working Party IV: CML | Working Party V: Pediatric ALL | Working Party VI: VTE | Working Party VII: Hemophilia |
| Session I 좌장: 이동순 |
MRD Practical Issue 좌장: 국 훈 |
Session 1: Gene Therapy – Basic to Clinical Practice 좌장: 박상규 |
||
| [13:40-14:20] Current status of MRD in clinic 김혜리 (울산의대) |
Session I: Laboratory Medicine for Thrombosis 좌장: 박노진/방수미 |
|||
| [13:40-14:10] How to establish standardized response monitoring in Korea: practical perspective 조영욱 (울산의대) |
[13:40-14:10] Genome editing using CRISPR 배상수 (한양대 화학과) |
|||
| [13:45-14:10] Laboratory evaluation for thrombophilia: when, what, and how??
장성수 (울산의대)
[14:10-14:20] 질의 응답, 토의 |
[14:10-14:40] Gene therapy for hemophilia: clinical perspectives 한재준 (경희의대) |
|||
| [14:10-14:40] Role of immune system associated with TKI therapy in CML
Noriyoshi Iriyama
(Nihon University, Tokyo, Japan)
|
[14:20-15:20] NGS and FACS based MRD measurement Brent Lee Wood (University of Washington) |
[14:20-14:45] Monitoring during DOAC treatment: when and how? 송재우(연세의대) [14:45-14:55] 질의 응답, 토의 |
||
| Break | ||||
| Session II 좌장: 정철원 |
좌장: 강형진 |
Session II: Clinical Medicine for Thrombosis 좌장: 김인호/김진석 |
Session 2: Extended Half-Life Coagulation Factor Products 좌장: 김순기 |
|
| [15:00-15:25]Management of advanced phase CML 엄지은 (한양의대) |
[15:30-16:30] Consensus Discussion | [15:10-15:35] Unusual site thrombosis: focus on splanchnic thrombosis
이지현 (동아의대) [15:35-15:45] 질의 응답, 토의 |
[15:00-15:30] The diverse class and manufacture of extended half life products 심예지 (계명의대) |
|
| [15:25-15:50]Management of CML refractory/ intolerable to TKI 정철원 (성균관의대) |
[15:45-16:10] Venous thromboembolic disease in hematological malignancies
홍준식 (서울의대) [16:10-16:20] 질의 응답, 토의 |
[15:30-16:00] Clinical application and reality of extended half life products : factor VIII and IX 유기영 (한국혈우재단) |
||
| [15:50-16:15]Efficacy and safety of ponatinib 공지현 (연세원주의대) |
[16:20 - 16:25] Closing Remark
오도연 (혈전증연구회 고문) |
[16:00-16:10] Discussion (All) | ||
| [16:15-16:30]Ongoing trials of CML Working Party 이혜원 (국립암센터) |
[16:10-16:40] 혈우병연구회 총회 | |||
